MainStreet Investment Advisors LLC Lowers Stock Holdings in Zoetis Inc. (NYSE:ZTS)

MainStreet Investment Advisors LLC trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 2.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,764 shares of the company’s stock after selling 412 shares during the period. MainStreet Investment Advisors LLC’s holdings in Zoetis were worth $2,405,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in ZTS. Atlantic Edge Private Wealth Management LLC lifted its position in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. lifted its position in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 166 shares during the period. Navigoe LLC purchased a new stake in shares of Zoetis in the 4th quarter worth approximately $30,000. Murphy & Mullick Capital Management Corp purchased a new stake in shares of Zoetis in the 4th quarter worth approximately $44,000. Finally, Asset Planning Inc purchased a new stake in shares of Zoetis in the 4th quarter worth approximately $58,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Down 0.9%

NYSE ZTS opened at $160.43 on Wednesday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a market cap of $71.42 billion, a PE ratio of 29.33, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a 50 day moving average price of $157.03 and a 200 day moving average price of $165.79. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same quarter in the prior year, the business posted $1.38 EPS. Zoetis’s revenue for the quarter was up 1.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71% decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

ZTS has been the subject of several research reports. Piper Sandler upped their price target on shares of Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a research report on Monday. Barclays upped their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Stifel Nicolaus lowered their price target on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Monday, April 14th. Morgan Stanley lowered their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $212.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.